T. Rowe Price Launches Three New Active ETFs in Biotech, Small-Cap, and Mid-Cap Sectors
T. Rowe Price has introduced three new actively managed exchange traded funds (ETFs) to expand its product lineup: the T. Rowe Price Biotech ETF (TDNA), the T. Rowe Price Small-Cap ETF (TSEE), and the T. Rowe Price Mid-Cap Equity Research ETF (TMID). These fully transparent ETFs began trading on NASDAQ, adding eight active offerings this year for a total of 38 funds in its lineup. The new ETFs aim to provide investors with access to specific market segments through active management strategies backed by T. Rowe Price's fundamental research capabilities. TDNA focuses on biotechnology companies and emerging technologies, while TSEE offers exposure to the U.S. small-cap equity market. TMID expands the firm’s Structured Research Strategies lineup using insights from its equity analysts. Each ETF is managed by experienced portfolio managers with strong tenure at T. Rowe Price. Expense ratios range between 0.47% and 0.59%, positioning them as competitive options in their respective categories.
